Which antibiotic covers MRSA and VRE?

Which antibiotic covers MRSA and VRE?

• A. Doxycycline
• B. Vancomycin
• C. Tigecycline
• D. Linezolid

Answer: (C)

This question targets antimicrobial coverage against two highly resistant organisms, MRSA and VRE. Among the options, the one that reliably covers both MRSA and VRE is Linezolid. It inhibits protein synthesis by binding to the 50S ribosomal subunit and has excellent oral bioavailability with both IV and oral forms, allowing seamless use across different infection sites. This makes it a versatile option for infections caused by MRSA and VRE, such as skin and soft tissue infections, pneumonia, and certain bloodstream infections. Doxycycline can address many MRSA infections but does not reliably cover VRE. Vancomycin treats MRSA but VRE are resistant to it, so it won’t cover VRE. Tigecycline does have activity against both MRSA and VRE inappropriately broad terms, but it provides low serum concentrations and is not ideal for bacteremia or bloodstream infections, limiting its usefulness when systemic coverage is required. So, Linezolid is the best choice for dual coverage of MRSA and VRE.

This question targets antimicrobial coverage against two highly resistant organisms, MRSA and VRE. Among the options, the one that reliably covers both MRSA and VRE is Linezolid. It inhibits protein synthesis by binding to the 50S ribosomal subunit and has excellent oral bioavailability with both IV and oral forms, allowing seamless use across different infection sites. This makes it a versatile option for infections caused by MRSA and VRE, such as skin and soft tissue infections, pneumonia, and certain bloodstream infections.

Doxycycline can address many MRSA infections but does not reliably cover VRE. Vancomycin treats MRSA but VRE are resistant to it, so it won’t cover VRE. Tigecycline does have activity against both MRSA and VRE inappropriately broad terms, but it provides low serum concentrations and is not ideal for bacteremia or bloodstream infections, limiting its usefulness when systemic coverage is required. So, Linezolid is the best choice for dual coverage of MRSA and VRE.